

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	90014390
	Filing Date	2019-10-16
	First Named Inventor	R. ZHAO
	Art Unit	3991
	Examiner Name	JONES, DWAYNE C
	Attorney Docket Number	0088597-000018

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2 922 818	EP	A0	2015-09-30	HANGZHOU DAC BIOTECH CO LTD		
	2	2014/080251	WO	A1	2014-05-30	HANGZHOU DAC BIOTECH CO., LTD.	Corresponds to EP2 922 818	
	3	1 625 857	EP	A2	2006-02-15	ROCHE DIAGNOSTICS GMBH et al.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		90014390	
	Filing Date		2019-10-16	
	First Named Inventor	R. ZHAO		
	Art Unit	3991		
	Examiner Name	JONES, DWAYNE C		
Attorney Docket Number		0088597-000018		

4	2008/015415	WO	A2	2008-02-07	GE HEALTHCARE UK LIMITED		
5	2009/134976	WO	A1	2009-11-05	IMMUNOGEN, INC.		
6	2009/134977	WO	A1	2009-11-05	IMMUNOGEN, INC.		
7	2012/153193	WO	A2	2012-11-15	LEGO-CHEM BIOSCIENCES, INC.		

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Decision to grant a European patent pursuant to Article 97(1) EPC issued on August 9, 2018, by the European Patent Office in corresponding European Patent Application No. 12888899.7. (2 pages)	
	2	Notice of Opposition and Grounds for Opposition filed on May 31, 2019, in the European Patent Office in corresponding European Patent No. 2922818. (300 pages)	
	3	Notice of Opposition and Statement of Facts and Arguments filed on June 3, 2019, in the European Patent Office in corresponding European Patent No. 2922818. (591 pages)	
	4	Communication of a notice of opposition issued on June 12, 2019, by the European Patent Office in corresponding European Patent No. 2922818. (46 pages)	
	5	Communication of notices of opposition (R. 79(1) EPC) issued on June 24, 2019, by the European Patent Office in corresponding European Patent No. 2922818. (5 pages)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		90014390
	Filing Date		2019-10-16
	First Named Inventor	R. ZHAO	
	Art Unit	3991	
	Examiner Name	JONES, DWAYNE C	
	Attorney Docket Number	0088597-000018	

6	Proprietor's reply to the oppositions filed on October 30, 2019, in the European Patent Office in corresponding European Patent No. 2922818. (87 pages)
7	Brief Communication issued on November 6, 2019, by the European Patent Office in corresponding European Patent No. 2922818. (156 pages)
8	Summons to attend oral proceedings issued on March 2, 2020, by the European Patent Office in corresponding European Patent No. 2922818. (20 pages)
9	Submission in opposition proceedings made following summons to attend oral proceedings filed on March 31, 2020, in the European Patent Office in corresponding European Patent No. 2922818. (253 pages)
10	~~Brief Communication issued on April 7, 2020, by the European Patent Office in corresponding European Patent No. 2922818. (126 pages)~~
11	~~Submission in opposition proceedings made following summons to attend oral proceedings filed on July 15, 2020, in the European Patent Office in corresponding European Patent No. 2922818. (253 pages)~~
12	Consolidated List of Opposition Citations in corresponding European Patent No. 2922818. (2 pages)
13	CHEREMISINOFF, Nicholas P., "Industrial Solvents Handbook", Second Edition, 2003. (3 pages)
14	LLEWELYN et al., "Superantigens: microbial agents that corrupt immunity", The Lancet Infectious Diseases, March 2002, Vol. 2, pp. 156-162.
15	MAMIDYALA et al., "In situ click chemistry: probing the binding landscapes of biological molecules", Chemical Society Review, 2010, Vol. 39, pp. 1252-1261.
16	MELDAL et al., "Cu-Catalyzed Azide-Alkyne Cycloaddition", Chemical Reviews, 2008, Vol. 108, No. 8, pp. 2952-3015.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		90014390
	Filing Date		2019-10-16
	First Named Inventor	R. ZHAO	
	Art Unit	3991	
	Examiner Name	JONES, DWAYNE C	
	Attorney Docket Number	0088597-000018	

17	MORALES-SANFRUTOS et al., "Vinyl Sulfone Bifunctional Tag Reagents for Single-Point Modification of Proteins", Organic & Biomolecular Chemistry, 2010, Vol. 8, pp. 667-675.
18	MORALES-SANFRUTOS et al., "Vinyl Sulfone Bifunctional Tag Reagents for Single-Point Modifications of Proteins", Journal of Organic Chemistry, 2010, Vol. 75, pp. 4039-4047.
19	STRAUS et al., "Unusual binding sites for horseradish peroxidase on the surface of cultured and isolated mammalian cells", Histochemistry, 1986, Vol. 85, pp. 277-285.
20	STRAUS et al., "Binding sites for horseradish peroxidase on the cell surface", Histochemistry, 1987, Vol. 86, pp. 453-457.
21	TEMMING et al., "Evaluation of RGD-Targeted Albumin Carriers for Specific Delivery of Auristatin E to Tumor Blood Vessels", Bioconjugate Chemistry, 2006, Vol. 17, pp. 1385-1394.
22	TSUCHIKAMA et al., "Antibody-drug conjugates: recent advances in conjugation and linker chemistries", Protein & Cell, 2018, Vol. 9, No. 1, pp. 33-46.
23	Ullmann's Encyclopaedia of Industrial Chemistry, "Sulfones and Sulfoxides", Ullmann's Encyclopaedia of Industrial Chemistry, 2000, Ed. Vol 34.
24	VANBRUNT et al., "Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry", Bioconjugate Chemistry, September 2, 2015, Vol. 26, No. 11. (12 pages)
25	WANG et al., "Binding of Serum Albumin on Tumor Cells and Characterization of the Albumin Binding Protein", Journal of Biochemistry, 1994, Vol. 115, pp. 898-903.
26	ZHAO et al., "Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates", The Journal of Medicinal Chemistry, 2011, Vol. 54, pp. 3606-3623.

If you wish to add additional non-patent literature document citation information please click the Add button

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		90014390
	Filing Date		2019-10-16
	First Named Inventor	R. ZHAO	
	Art Unit	3991	
	Examiner Name	JONES, DWAYNE C	
	Attorney Docket Number	0088597-000018	

EXAMINER SIGNATURE			
Examiner Signature	/Dwayne C. Jones/		Date Considered
			09/10/2020
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		90014390
	Filing Date		2019-10-16
	First Named Inventor	R. ZHAO	
	Art Unit	3991	
	Examiner Name	JONES, DWAYNE C	
	Attorney Docket Number	0088597-000018	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Fang Liu/	Date (YYYY-MM-DD)	2020-08-13
Name/Print	Fang Liu	Registration Number	51,283

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.